17 October 2024NewsAmericasMarisa Woutersen

LSPN Fall: Why Big Pharma is facing 'a balancing act'

As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK fires pair of COVID and RSV lawsuits at Moderna

16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.

Europe

Roche to outside counsel: ‘Law firms must adapt to the modern world’

9 October 2024 Roche’s chief trademark officer has more than filing and searches on his to-do list—and external counsel must keep up, he tells Marisa Woutersen.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

LSPN Fall: Why Big Pharma is facing 'a balancing act'

More on this story

Editor's picks

Editor's picks

More features